ISDA: 5EXM

Deposition Date 2015-11-23

Release Date 2016-04-13

Last Version Date 2024-10-23

Entry Detail

PDB ID:

5EXM

Keywords:

HYDROLASE/HYDROLASE INHIBITOR

Title:

FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[4-(aminomethyl)cyclohexyl]carbonylamino]-2-phenyl-ethyl]pyridin-4-yl]phenyl]carbamate

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.09 Å

R-Value Free:

0.22

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 32 2 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Coagulation factor XIa light chain
Gene (Uniprot):F11
Mutagens:N113G,T115G
Chain IDs:A
Chain Length:244
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P03951 Pfam ID:PF00089 EC:3.4.21.27

Ligand Molecules

5ST

EDO

SO4

Primary Citation

Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group

Corte, J.R, Fang, T, Pinto, D.J.P, Orwat, M.J, Han, W, Rendina, A.R, Luettgen, J.M, Rossi, K.A, Wei, A, Ramamurthy, V, Myers Jr, J.E, Sheriff, S, Narayanan, R, Harper, T, Zheng, J.J, Li, Y.-X, Seiffert, D.A, Wexler, R.R, Quan, M.L, Quan, M.L, Wong, P.C, Wang, C, Woerner, F, Smallheer, J.M, Barbera, F.A, Bozarth, J.M, Brown, R.L, Harpel, M.R, Luettgen, J.M, Morin, P.E, Peterson, T, Ramamurthy, V, Rendina, A.R, Rossi, K.A, Watson, C.A, Wei, A, Zhang, G, Seiffert, D, Wexler, R.R, Hangeland, J.J, Friends, T.J, Rossi, K.A, Smallheer, J.M, Wang, C, Sun, Z, Corte, J.R, Fang, T, Wong, P.C, Rendina, A.R, Barbera, F.A, Bozarth, J.M, Luettgen, J.M, Watson, C.A, Zhang, G, Wei, A, Ramamurthy, V, Morin, P.E, Bisacchi, G.S, Subramaniam, S, Arunachalam, P, Mathur, A, Seiffert, D.A, Wexler, R.R, Quan, M.L, Corte, J.R, Fang, T, Hangeland, J.J, Friends, T.J, Rendina, A.R, Luettgen, J.M, Bozarth, J.M, Barbera, F.A, Rossi, K.A, Wei, A, Ramamurthy, V, Morin, P.E, Seiffert, D.A, Wexler, R.R, Quan, M.L, Pinto, D.J.P, Smallheer, J.M, Corte, J.R, Austin, E.J.D, Wang, C, Fang, T, Smith II, L.M, Rossi, K.A, Rendina, A.R, Bozarth, J.M, Zhang, G, Wei, A, Ramamurthy, V, Sheriff, S, Myers Jr, J.E, Morin, P.E, Luettgen, J.M, Seiffert, D.A, Quan, M.L, Wexler, R.R, Hu, Z, Wong, P.C, Gilligan, P.J, Han, W, Pabbisetty, K.B, Bozarth, J.M, Crain, E.J, Harper, T, Luettgen, J.M, Myers Jr, J.E, Ramamurthy, V, Rossi, K.A, Sheriff, S, Watson, C.A, Wei, A, Zheng, J.J, Seiffert, D.A, Wexler, R.R, Quan, M.L, Smith II, L.M, Orwat, M.J, Hu, Z, Han, W, Wang, C, Rossi, K.A, Gilligan, P.J, Pabbisetty, K.B, Osuna, H, Corte, J.R, Rendina, A.R, Luettgen, J.M, Wong, P.C, Narayanan, R, Harper, T, Bozarth, J.M, Crain, E.J, Wei, A, Ramamurthy, V, Morin, P.E, Seiffert, D.A, Quan, M.L, Lam, P.Y.S, Wexler, R.R, Pinto, D.J.P.Show

Bioorg.Med.Chem. 24 2257 2272 (2016)

PMID: 27073051 DOI: 10.1016/j.bmc.2016.03.062

Abstact

Pyridine-based Factor XIa (FXIa) inhibitor (S)-2 was optimized by modifying the P2 prime, P1, and scaffold regions. This work resulted in the discovery of the methyl N-phenyl carbamate P2 prime group which maintained FXIa activity, reduced the number of H-bond donors, and improved the physicochemical properties compared to the amino indazole P2 prime moiety. Compound (S)-17 was identified as a potent and selective FXIa inhibitor that was orally bioavailable. Replacement of the basic cyclohexyl methyl amine P1 in (S)-17 with the neutral p-chlorophenyltetrazole P1 resulted in the discovery of (S)-24 which showed a significant improvement in oral bioavailability compared to the previously reported imidazole (S)-23. Additional improvements in FXIa binding affinity, while maintaining oral bioavailability, was achieved by replacing the pyridine scaffold with either a regioisomeric pyridine or pyrimidine ring system.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form